脑病用药递送策略及临床研究进展  

Drug delivery strategies and clinical research progress for encephalopathy

作　　者：陆宁姝 嵇涛 卢瑛蓝 许熙媛 顾晓晨 丁杨[1] LU Ningshu;JI Tao;LU Yinglan;XU Xiyuan;GU Xiaochen;DING Yang(Department of Pharmaceutics&State Key Laboratory of Natural Medicines,China Pharmaceutical University,Nanjing 210009,China;College of Pharmacy,University of Manitoba,Winnipeg MB R3E 0T5,Canada)

机构地区：[1]中国药科大学药剂系,多靶标天然药物全国重点实验室,南京211198 [2]曼尼托巴大学药学院,加拿大温尼伯MB R3E 0T5

出　　处：《中国药科大学学报》2024年第5期577-589,共13页Journal of China Pharmaceutical University

基　　金：国家自然科学基金项目(No.82372113,No.82073401);国家高层次青年人才计划项目;江苏省杰出青年基金项目(BK20240096)。

摘　　要：血脑屏障的存在限制了药物的脑内有效递送,导致脑病疗效不佳,难以满足患者的临床需求。近年来,基于优效给药途径和新型递药系统等策略开发的创新制剂,能够突破血脑屏障的桎梏,显著提升药物的入脑效率及降低外周不良反应的发生率,为患者带来重大治疗意义。本文对脑病用药在临床研究中存在的关键问题进行分析,详尽综述了脑病治疗领域内全球创新药物制剂的发展及研发策略,并展望未来治疗策略的应用前景,以期为新一代药物研发提供新思路和方法。The blood-brain barrier in humans significantly restricts the effective delivery of drugs into the brain,resulting in poor therapeutic efficacy and difficulty in brain disease management.In recent years,innovative strategies and novel preparations have been studied and developed in order to circumvent the blood-brain barrier,achieve efficient drug entry into the brain,minimize the incidence of peripheral adverse effects,and bring significant therapeutic outcomes to patients.This review summarizes some key development strategies for treating encephalopathy,to provide some insights for the development of the next generation of drugs.

关 键 词：脑病用药 药物递送 血脑屏障 开发策略 临床进展 

分 类 号：R944[医药卫生—药剂学] R749[医药卫生—药学]